Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00106145
First received: March 21, 2005
Last updated: February 21, 2014
Last verified: February 2014